Technical Analysis for SLS - SELLAS Life Sciences Group, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 1.19 | 0.85% | 0.01 |
Earnings due: Nov 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Flat | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Crossed Above 200 DMA | Bullish | 0.00% | |
Gapped Down | Weakness | 0.00% | |
20 DMA Resistance | Bearish | 0.85% | |
Fell Below 200 DMA | Bearish | 0.85% | |
MACD Bearish Signal Line Cross | Bearish | 0.85% | |
Fell Below 20 DMA | Bearish | 0.00% | |
200 DMA Support | Bullish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.25% | |
20 DMA Support | Bullish | -3.25% |
Alert | Time |
---|---|
20 DMA Resistance | about 19 hours ago |
Rose Above 20 DMA | about 19 hours ago |
Up 2% | about 19 hours ago |
Up 1% | about 20 hours ago |
Reversed from Down | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
SELLAS Life Sciences Group, Inc. Description
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Solid Tumors Cancer Treatment Oncology Breast Cancer Acute Myeloid Leukemia Immunotherapies Antineoplastic Drugs Ovarian Cancer Treatment Of Breast Cancer Hematologic Malignancies Oncolytics Biotech Treatment Of Acute Myeloid Leukemia Novel Cancer Endometrial Cancer Pembrolizumab Gynaecological Cancer Gynaecology Ovarian And Endometrial Cancers
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.72 |
52 Week Low | 0.4986 |
Average Volume | 506,489 |
200-Day Moving Average | 1.18 |
50-Day Moving Average | 1.24 |
20-Day Moving Average | 1.21 |
10-Day Moving Average | 1.18 |
Average True Range | 0.07 |
RSI (14) | 47.09 |
ADX | 22.31 |
+DI | 16.54 |
-DI | 27.36 |
Chandelier Exit (Long, 3 ATRs) | 1.11 |
Chandelier Exit (Short, 3 ATRs) | 1.27 |
Upper Bollinger Bands | 1.29 |
Lower Bollinger Band | 1.12 |
Percent B (%b) | 0.4 |
BandWidth | 14.24 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0004 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.30 | ||||
Resistance 3 (R3) | 1.29 | 1.25 | 1.28 | ||
Resistance 2 (R2) | 1.25 | 1.22 | 1.25 | 1.27 | |
Resistance 1 (R1) | 1.22 | 1.21 | 1.24 | 1.23 | 1.27 |
Pivot Point | 1.18 | 1.18 | 1.19 | 1.18 | 1.18 |
Support 1 (S1) | 1.15 | 1.15 | 1.17 | 1.16 | 1.11 |
Support 2 (S2) | 1.11 | 1.14 | 1.11 | 1.11 | |
Support 3 (S3) | 1.08 | 1.11 | 1.10 | ||
Support 4 (S4) | 1.09 |